KalVista Pharmaceuticals (KALV) Enterprise Value: 2014-2025
Historic Enterprise Value for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to $684.6 million.
- KalVista Pharmaceuticals' Enterprise Value rose 155.03% to $684.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was $684.6 million, marking a year-over-year increase of 2138.74%. This contributed to the annual value of $684.6 million for FY2025, which is 155.03% up from last year.
- Latest data reveals that KalVista Pharmaceuticals reported Enterprise Value of $684.6 million as of Q2 2025, which was up 355.70% from $150.2 million recorded in Q4 2024.
- KalVista Pharmaceuticals' Enterprise Value's 5-year high stood at $684.6 million during Q2 2025, with a 5-year trough of $150.2 million in Q4 2024.
- Its 3-year average for Enterprise Value is $342.9 million, with a median of $290.1 million in 2024.
- Data for KalVista Pharmaceuticals' Enterprise Value shows a peak YoY surged of 155.03% (in 2025) over the last 5 years.
- Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Enterprise Value stood at $222.4 million in 2021, then reached $188.9 million in 2023, then surged by 65.00% to $150.2 million in 2024, then skyrocketed by 155.03% to $684.6 million in 2025.
- Its Enterprise Value was $684.6 million in Q2 2025, compared to $150.2 million in Q4 2024 and $311.7 million in Q4 2024.